Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- therapeutics histones p300/CBP-Associated Factors pCAF GNAT GCN5-related N-acetyltransferases acetylates lysines N-terminal terminus tails H3 H4 tumors suppressor genes PTEN human cancers apoptosis fluorescence fluorescent inhibitors fluorometric assays
- Product Overview:
Cayman’s Histone Acetyltransferase (HAT) Inhibitor Screening Assay Kit provides a fast, fluorescence-based method for evaluating PCAF HAT inhibitors. The procedure requires only three easy steps, all performed in the same microwell plate. Cayman’s Histone Acetyltransferase (HAT) Inhibitor Screening Assay Kit provides a fast, fluorescence-based method for evaluating PCAF HAT inhibitors. The procedure requires only three easy steps, all performed in the same microwell plate. In the first step of the protocol, HAT is incubated with acetyl-CoA and the histone H3 peptide. During this time, HAT catalyzes the enzymatic transfer of acetyl groups from acetyl-CoA to the H3 peptide producing an acetylated peptide and CoASH. Following addition of isopropanol to stop the enzymatic reaction, CPM is added to the wells of the plate. CPM reacts with the free thiol groups present on CoASH forming a highly fluorescent product that is detected using excitation and emission wavelengths of 360-390 and 450-470 nm, respectively.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.